NEW AMGEN DATA AT ESC 2022 SHOW LONG-TERM LDL-C LOWERING WITH REPATHA® (EVOLOCUMAB) WAS WELL-TOLERATED FOR MORE THAN 8 YEARS

Go back to NEW AMGEN DATA AT ESC 2022 SHOW LONG-TERM LDL-C LOWERING WITH REPATHA® (EVOLOCUMAB) WAS WELL-TOLERATED FOR MORE THAN 8 YEARS
Amgen Inc (NASDAQ: AMGN) Delayed: 393.17 --0 (-0%)
Previous Close $393.17    52 Week High $176.85 
Open $393.17    52 Week Low $133.64 
Day High $393.17    P/E 59.21 
Day Low $393.17    EPS $6.64 
Volume 1,967